Literature DB >> 24493627

Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces.

Michela Rosini1, Elena Simoni, Anna Minarini, Carlo Melchiorre.   

Abstract

In recent years, the multi-target-directed ligand concept has been used to design a variety of molecules hitting different biological targets for Alzheimer's disease. We have sought to combine, in the same molecule, the neuroprotective action of N-methyl-D-aspartate receptor antagonism with the symptomatic relief offered by cholinergic activity through acetylcholinesterase inhibition. This strategy could potentially maintain the positive outcomes of memantine-acetylcholinesterase inhibitor combinations, but with the benefits of a single molecule therapy. Herein, we discuss selected examples of multifunctional compounds, which we rationally designed to simultaneously modulate these targets. We also examine the intertwined relationship between acetylcholinesterase, N-methyl-D-aspartate receptors, and other active players in the neurotoxic cascade.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24493627     DOI: 10.1007/s11064-014-1250-1

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  70 in total

1.  Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons.

Authors:  M Hartbauer; B Hutter-Paier; G Skofitsch; M Windisch
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

Review 2.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

Review 3.  Combination therapy for Alzheimer's disease.

Authors:  Laxeshkumar Patel; George T Grossberg
Journal:  Drugs Aging       Date:  2011-07-01       Impact factor: 3.923

4.  Synergistic effects of galantamine and memantine in attenuating scopolamine-induced amnesia in mice.

Authors:  Perrine Busquet; Valeria Capurro; Andrea Cavalli; Daniele Piomelli; Angelo Reggiani; Rosalia Bertorelli
Journal:  J Pharmacol Sci       Date:  2012-11-13       Impact factor: 3.337

Review 5.  Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors.

Authors:  Ana Castro; Ana Martinez
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

6.  The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-β42 with memantine.

Authors:  Csaba Nyakas; Ivica Granic; László G Halmy; Pradeep Banerjee; Paul G M Luiten
Journal:  Behav Brain Res       Date:  2010-05-27       Impact factor: 3.332

Review 7.  Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease.

Authors:  D Muñoz-Torrero
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 8.  From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer's disease.

Authors:  Maria Laura Bolognesi; Anna Minarini; Michela Rosini; Vincenzo Tumiatti; Carlo Melchiorre
Journal:  Mini Rev Med Chem       Date:  2008-09       Impact factor: 3.862

Review 9.  Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.

Authors:  Chris G Parsons; Albrecht Stöffler; Wojciech Danysz
Journal:  Neuropharmacology       Date:  2007-08-10       Impact factor: 5.250

Review 10.  Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease.

Authors:  Chris G Parsons; Wojciech Danysz; Andrzej Dekundy; Irena Pulte
Journal:  Neurotox Res       Date:  2013-05-09       Impact factor: 3.911

View more
  20 in total

1.  Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment.

Authors:  Cédric Lecoutey; Damien Hedou; Thomas Freret; Patrizia Giannoni; Florence Gaven; Marc Since; Valentine Bouet; Céline Ballandonne; Sophie Corvaisier; Aurélie Malzert Fréon; Serge Mignani; Thierry Cresteil; Michel Boulouard; Sylvie Claeysen; Christophe Rochais; Patrick Dallemagne
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-25       Impact factor: 11.205

2.  The impact of crystallization conditions on structure-based drug design: A case study on the methylene blue/acetylcholinesterase complex.

Authors:  Orly Dym; Wanling Song; Clifford Felder; Esther Roth; Valery Shnyrov; Yacov Ashani; Yechun Xu; Robbie P Joosten; Lev Weiner; Joel L Sussman; Israel Silman
Journal:  Protein Sci       Date:  2016-03-28       Impact factor: 6.725

3.  Identification of a novel endophytic fungus from Huperzia serrata which produces huperzine A.

Authors:  Shaohua Shu; Xinmei Zhao; Wenjuan Wang; Guowei Zhang; Andreea Cosoveanu; Youngjoon Ahn; Mo Wang
Journal:  World J Microbiol Biotechnol       Date:  2014-09-12       Impact factor: 3.312

4.  Natural Xanthones from Garcinia mangostana with Multifunctional Activities for the Therapy of Alzheimer's Disease.

Authors:  Sheng-Nan Wang; Qian Li; Ming-Hua Jing; Espargaró Alba; Xiao-Hong Yang; Raimon Sabaté; Yi-Fan Han; Rong-Biao Pi; Wen-Jian Lan; Xiao-Bo Yang; Jing-Kao Chen
Journal:  Neurochem Res       Date:  2016-04-02       Impact factor: 3.996

5.  Donecopride, a Swiss army knife with potential against Alzheimer's disease.

Authors:  Christophe Rochais; Cédric Lecoutey; Katia Hamidouche; Patrizia Giannoni; Florence Gaven; Eleazere Cem; Serge Mignani; Kevin Baranger; Thomas Freret; Joël Bockaert; Santiago Rivera; Michel Boulouard; Patrick Dallemagne; Sylvie Claeysen
Journal:  Br J Pharmacol       Date:  2020-02-11       Impact factor: 8.739

6.  Genome-wide association study of language performance in Alzheimer's disease.

Authors:  Kacie D Deters; Kwangsik Nho; Shannon L Risacher; Sungeun Kim; Vijay K Ramanan; Paul K Crane; Liana G Apostolova; Andrew J Saykin
Journal:  Brain Lang       Date:  2017-05-31       Impact factor: 2.381

Review 7.  AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer's Disease.

Authors:  Yu Wang; Hao Wang; Hong-zhuan Chen
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

8.  In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer's Disease.

Authors:  Angelo M Reggiani; Elena Simoni; Roberta Caporaso; Johann Meunier; Emeline Keller; Tangui Maurice; Anna Minarini; Michela Rosini; Andrea Cavalli
Journal:  Sci Rep       Date:  2016-09-09       Impact factor: 4.379

9.  Novel conjugates of aminoadamantanes with carbazole derivatives as potential multitarget agents for AD treatment.

Authors:  Sergey O Bachurin; Elena F Shevtsova; Galina F Makhaeva; Vladimir V Grigoriev; Natalia P Boltneva; Nadezhda V Kovaleva; Sofya V Lushchekina; Pavel N Shevtsov; Margarita E Neganova; Olga M Redkozubova; Elena V Bovina; Alexey V Gabrelyan; Vladimir P Fisenko; Vladimir B Sokolov; Alexey Yu Aksinenko; Valentina Echeverria; George E Barreto; Gjumrakch Aliev
Journal:  Sci Rep       Date:  2017-03-30       Impact factor: 4.379

10.  Conjugates of γ-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease.

Authors:  Galina F Makhaeva; Sofya V Lushchekina; Natalia P Boltneva; Vladimir B Sokolov; Vladimir V Grigoriev; Olga G Serebryakova; Ekaterina A Vikhareva; Alexey Yu Aksinenko; George E Barreto; Gjumrakch Aliev; Sergey O Bachurin
Journal:  Sci Rep       Date:  2015-08-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.